Reata Pharmaceuticals Inc - Ordinary Shares - Class A

-1.96 (-4.95%)
5:58:36 PM EDT: $37.75 +0.09 (+0.24%)
Regulatory, Earnings Announcements

Reata Pharmaceuticals Reports Q3 Adjusted Loss Of $1.47 Per Share

Published: 11/08/2022 11:50 GMT
Reata Pharmaceuticals Inc - Ordinary Shares - Class A (RETA) - Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs.
NDA for Omaveloxolone for Patients With Friedreich's Ataxia Under Review With PDUFA Date of February 28, 2023.
Reata Pharmaceuticals - FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss Omaveloxolone NDA and Late Cycle Meeting Has Been Completed.
Plan to Submit an Maa to European Medicines Agency ("ema") for Omaveloxolone This Year.
Qtrly Adjusted Loss per Share $1.47.
Reata Pharmaceuticals - Existing Cash,cash Equivalents,marketable Debt Securities to Be Sufficient to Enable It to Fund Operations Through End of 2024.
GAAP Net Loss for Q3 of 2022, Was $79.0 Million, Or $2.16 per Share.
Q3 Earnings per Share View $-2.18 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.49 Million
Adjusted EPS is expected to be -$2.19

Next Quarter Revenue Guidance is expected to be $0.14 Million
Next Quarter EPS Guidance is expected to be -$2.27

More details on our Analysts Page.